<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="cases, plasma from recently cured patients [10,11,12,13]. Antimalarial agents like" exact="chloroquine" post="are used to block the virus entry, while new"/>
 <result pre="the virus entry, while new drugs like tocilizumab, anakinra or" exact="ruxolitinib" post="[14], directed against a specific key element of the"/>
 <result pre="inhibitor, it has been shown, alone or in combination with" exact="chloroquine" post="or interferon-Î², to effectively block the replication of SARS-CoV-2"/>
 <result pre="Peramivir, Zanamivir, etc.), Ganciclovir, Aciclovir and Rribavirin, as well as" exact="methylprednisolone" post="[42,43] for the influenza virus, are not valid for"/>
 <result pre="for COVID-19 and are not recommended. Another effective drug is" exact="chloroquine" post="(500 mg every 12 h) and hydroxychloroquine (200 mg"/>
 <result pre="effective drug is chloroquine (500 mg every 12 h) and" exact="hydroxychloroquine" post="(200 mg every 12 h), drugs used for many"/>
 <result pre="treatment of rheumatoid arthritis. Several possible mechanisms have been studied." exact="Chloroquine" post="can inhibit the pH-dependent phases of the replication of"/>
 <result pre="effect on the infection and spread of SARS-CoV [45]. Furthermore," exact="chloroquine" post="has immuno-modulatory effects, suppressing the production/release of TNF-Î± and"/>
 <result pre="production/release of TNF-Î± and IL-6. Several studies have found that" exact="chloroquine" post="interferes with the glycosylation of SARS-CoV cell receptors [45],"/>
 <result pre="inhibition of viral replication [50,51]. The best-known proteasome inhibitor is" exact="Bortezomib" post="(Valcade) [50], which was approved in 2008 as a"/>
 <result pre="(Figure 2) [49,52]. Interestingly, Computational Drug Repurposing Studies showed that" exact="Carfilzomib" post="is a good candidate for the treatment of COVID-19"/>
 <result pre="A and tripeptidyl peptidase II) [67], Eepoxomomine, Llactacystine and Velcade" exact="Bortezomib" post="affect the proteasome more specifically [68,69,70]. Finally, a 2012"/>
 <result pre="the activation of the UPS. In the few papers published," exact="bortezomib" post="did not show great efficacy, but we have new"/>
 <result pre="dynamics simulation followed by binding free energy calculations, demonstrating that" exact="Carfilzomib" post="presented the best binding free energy, and therefore supporting"/>
 <result pre="molecules appear to be promising candidates; in particular, MG132, epoxomycin," exact="bortezomib" post="and carfilzomib have the potential to affect both viral"/>
 <result pre="to be promising candidates; in particular, MG132, epoxomycin, bortezomib and" exact="carfilzomib" post="have the potential to affect both viral replication as"/>
 <result pre="coronavirus in the United StatesN. Engl. J. Med.202010.1056/NEJMoa2001191 41.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="CoronavirusZhonghua Jie He He Hu Xi Za Zhi202010.3760/cma.j.issn.1001-0939.2020.03.004 44.SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: An old drug against todayâ€™s diseases?Lancet"/>
</results>
